<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02062073</url>
  </required_header>
  <id_info>
    <org_study_id>Ha03-006</org_study_id>
    <nct_id>NCT02062073</nct_id>
  </id_info>
  <brief_title>Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion</brief_title>
  <official_title>A Randomized, Controlled Study to Evaluate the Sensitizing Potential of Abametapir Lotion in Healthy Volunteers Using a Repeat Insult Patch Test Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TKL Research, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Accelovance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of this study will be to determine the potential of abametapir lotion to induce&#xD;
      sensitization by repeated topical application to the healthy skin of humans under controlled&#xD;
      conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to evaluate the sensitizing potential of abametapir lotion using repeat insult patch test design</measure>
    <time_frame>8 weeks</time_frame>
    <description>Evaluation of dermal reactions at the application sites will be assessed clinically using a visual scale that rates the degree of erythema, edema, and other signs of cutaneous irritation</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">238</enrollment>
  <condition>Head Lice</condition>
  <arm_group>
    <arm_group_label>Abametapir Lotion 0.74%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Lotion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.1% sodium lauryl sulfate</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Concurrent control 0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline 0.9%</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Concurrent control 0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abametapir Lotion 0.74% w/w</intervention_name>
    <arm_group_label>Abametapir Lotion 0.74%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>0.1% sodium lauryl sulfate</intervention_name>
    <arm_group_label>0.1% sodium lauryl sulfate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>saline 0.9%</intervention_name>
    <arm_group_label>Saline 0.9%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle Lotion</intervention_name>
    <arm_group_label>Vehicle Lotion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Are healthy (to be confirmed by medical history) males or females, 18 years of age or&#xD;
             older;&#xD;
&#xD;
          2. In the case of females of childbearing potential, are using an acceptable form of&#xD;
             birth control (oral/implant/injectable/transdermal contraceptives, intrauterine&#xD;
             device, condom with spermicide, diaphragm with spermicide, abstinence, partner's&#xD;
             vasectomy). Abstinence or vasectomized partner are acceptable if the female subject&#xD;
             agrees to implement one of the other acceptable methods of birth control if her&#xD;
             lifestyle/partner changes;&#xD;
&#xD;
          3. If female of childbearing potential, have a negative urine pregnancy test at Day 1,&#xD;
             and are willing to submit to a pregnancy test at the end of study;&#xD;
&#xD;
          4. Are free of any systemic or dermatologic disorder, which, in the opinion of the&#xD;
             investigator, will interfere with the study results or increase the risk of adverse&#xD;
             events;&#xD;
&#xD;
          5. Are of any skin type or race, providing the skin pigmentation will allow discernment&#xD;
             of erythema;&#xD;
&#xD;
          6. Complete a patch study Medical Screening form as well as a Medical Personal History&#xD;
             form; and&#xD;
&#xD;
          7. Read, understand, and provide signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have any visible skin disease at the application site which, in the opinion of the&#xD;
             investigative personnel, will interfere with the evaluation of the test site reaction;&#xD;
&#xD;
          2. Are not willing to refrain from using topical/systemic analgesics such as aspirin&#xD;
             (daily use of 81 mg aspirin is acceptable), Aleve, Motrin, Advil, or Nuprin for 72&#xD;
             hours prior to and during the study (occasional use of acetaminophen will be&#xD;
             permitted);&#xD;
&#xD;
          3. Are using inhaled/systemic/topical corticosteroids in the 3 weeks prior to and during&#xD;
             the study, or systemic/topical antihistamines for 72 hours prior to and during the&#xD;
             study;&#xD;
&#xD;
          4. Are using medication which, in the opinion of the investigative personnel, will&#xD;
             interfere with the study results, including anti-inflammatory medications;&#xD;
&#xD;
          5. Are unwilling or unable to refrain from the use of sunscreens, cosmetics, creams,&#xD;
             ointments, lotions, or similar products on the back during the study;&#xD;
&#xD;
          6. Have psoriasis and/or active atopic dermatitis/eczema;&#xD;
&#xD;
          7. Are females who are pregnant, plan to become pregnant during the study, or are&#xD;
             breast-feeding a child;&#xD;
&#xD;
          8. Have a known sensitivity to constituents present in the material being evaluated;&#xD;
&#xD;
          9. Have damaged skin in or around the test sites, including sunburn, excessively deep&#xD;
             tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other&#xD;
             disfigurations of the test site;&#xD;
&#xD;
         10. Have received treatment for any type of internal cancer within 5 years prior to study&#xD;
             entry;&#xD;
&#xD;
         11. Have a history of, or are currently being treated for skin cancer;&#xD;
&#xD;
         12. Are currently participating in any other clinical trial;&#xD;
&#xD;
         13. Have any known sensitivity to adhesives; and/or&#xD;
&#xD;
         14. Have received any investigational treatment(s) within 4 weeks prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Dosik</last_name>
    <role>Principal Investigator</role>
    <affiliation>TKL Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TKL Reserach</name>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <zip>07652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 11, 2014</study_first_submitted>
  <study_first_submitted_qc>February 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2014</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>head lice</keyword>
  <keyword>Hatchtech</keyword>
  <pending_results>
    <submitted>May 15, 2021</submitted>
    <returned>June 9, 2021</returned>
    <submitted>June 12, 2021</submitted>
    <returned>July 2, 2021</returned>
    <submitted>July 3, 2021</submitted>
    <returned>July 23, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

